|
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
NOT_RECRUITINGPhase 2Sponsored by Ascletis Pharma (China) Co., Limited
No longer actively recruiting
PhasePhase 2
SponsorAscletis Pharma (China) Co., Limited
Started2026-01
Est. completion2026-08
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
Locations8 sites
View on ClinicalTrials.gov →
NCT07321678
Summary
This randomized, double-blind, placebo-controlled Phase II study is designed to evaluate the efficacy, safety, and tolerability of ASC30 oral tablets formulation in participants with Type 2 Diabetes Mellitus
Eligibility
Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria: * Have Type 2 Diabetes (T2D) * Have HbA1c ≥7.0% to ≤10.5% as determined by the central laboratory at screening. * Stable body weight (less than 5% self-reported change within the previous 3 months). * Have a BMI ≥23.0 kilogram/square meter (kg/m²) at screening. Exclusion Criteria: * Have any prior diagnosis of type 1 diabetes mellitus (T1DM), or rare forms of diabetes mellitus * Have had more than 1 episode of severe hypoglycemia * Have poorly controlled hypertension * Have acute or chronic hepatitis and pancreatitis * Have evidence of a significant active and uncontrolled medical condition
Conditions2
DiabetesT2DM (Type 2 Diabetes Mellitus)
Interventions1
Locations8 sites
Ascletis Clinical Site
Ascletis Clinical Site
Find trials near these locations
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
No longer actively recruiting
PhasePhase 2
SponsorAscletis Pharma (China) Co., Limited
Started2026-01
Est. completion2026-08
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
Locations8 sites
View on ClinicalTrials.gov →
NCT07321678